Boundless Bio, Inc.
NASDAQ Global SelectTotal Valuation
Boundless Bio, Inc. carries a market capitalization of 64.50M, placing it among publicly traded companies globally. Its enterprise value stands at -16.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 64.50M |
| Enterprise Value | -16.44M |
Share Statistics
Boundless Bio, Inc. currently has 22.48M shares outstanding.
| Shares Outstanding | 22.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | -1.00 |
| P/OCF Ratio | -1.00 |
Financial Position
Boundless Bio, Inc. maintains a current ratio of 9.48, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.48 |
| Quick Ratio | 9.35 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -67.86 |
| Return on Assets (ROA) | -50.56 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Boundless Bio, Inc.'s stock has gained approximately 153.9823% over the past 52 weeks. The 50-day moving average sits at 2.66, while the 200-day moving average is 1.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | 153.9823% |
| 50-Day Moving Average | 2.66 |
| 200-Day Moving Average | 1.63 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -65.85M, while operating income came in at -68.01M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -68.01M |
| Pretax Income | -64.01M |
| Net Income | -64.01M |
| EBITDA | -65.85M |
| EBIT | -68.01M |
| Earnings Per Share (EPS) | -2.86 |
Balance Sheet
Total book value stands at 65.98M, with working capital of 65.88M providing operational flexibility.
| Cash & Cash Equivalents | 72.63M |
| Total Debt | N/A |
| Net Debt | -20.21M |
| Equity (Book Value) | 65.98M |
| Book Value Per Share | 2.94 |
| Working Capital | 65.88M |
Cash Flow
Boundless Bio, Inc. produced -56.25M in operating cash flow over the past twelve months. After subtracting -485,000.00 in capital expenditures, free cash flow totaled -56.73M - equivalent to -2.53 per share.
| Operating Cash Flow | -56.25M |
| Capital Expenditures | -485,000.00 |
| Free Cash Flow | -56.73M |
| FCF Per Share | -2.53 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.17 |
| FCF Yield | -99.53 |
Scores
Boundless Bio, Inc. posts an Altman Z-Score of -3.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.27 |